Pharmanutra SpA
MIL:PHN
Income Statement
Earnings Waterfall
Pharmanutra SpA
Revenue
|
100.2m
EUR
|
Cost of Revenue
|
-2.4m
EUR
|
Gross Profit
|
97.8m
EUR
|
Operating Expenses
|
-74.4m
EUR
|
Operating Income
|
23.4m
EUR
|
Other Expenses
|
-10.6m
EUR
|
Net Income
|
12.8m
EUR
|
Income Statement
Pharmanutra SpA
Dec-2017 | Jun-2018 | Dec-2018 | Jun-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||
Revenue |
38
N/A
|
41
+10%
|
47
+13%
|
50
+6%
|
54
+8%
|
58
+8%
|
56
-2%
|
71
+25%
|
74
+4%
|
91
+23%
|
68
-25%
|
104
+53%
|
111
+7%
|
115
+3%
|
83
-28%
|
127
+53%
|
137
+8%
|
138
+1%
|
100
-27%
|
|
Gross Profit | ||||||||||||||||||||
Cost of Revenue |
(2)
|
(2)
|
(2)
|
(2)
|
(3)
|
(3)
|
(3)
|
(3)
|
(4)
|
(4)
|
(2)
|
(3)
|
(3)
|
(4)
|
(3)
|
(3)
|
(3)
|
(2)
|
(2)
|
|
Gross Profit |
36
N/A
|
39
+9%
|
44
+12%
|
47
+7%
|
51
+8%
|
55
+8%
|
54
-2%
|
67
+25%
|
70
+4%
|
87
+24%
|
66
-24%
|
101
+53%
|
108
+7%
|
111
+3%
|
80
-28%
|
124
+55%
|
134
+8%
|
136
+1%
|
98
-28%
|
|
Operating Income | ||||||||||||||||||||
Operating Expenses |
(27)
|
(30)
|
(32)
|
(35)
|
(39)
|
(40)
|
(40)
|
(50)
|
(52)
|
(63)
|
(47)
|
(72)
|
(77)
|
(79)
|
(57)
|
(88)
|
(97)
|
(100)
|
(74)
|
|
Selling, General & Administrative |
(26)
|
(29)
|
(33)
|
(35)
|
(38)
|
(39)
|
(39)
|
(49)
|
(50)
|
(61)
|
(46)
|
(70)
|
(75)
|
(77)
|
(55)
|
(86)
|
(94)
|
(97)
|
(71)
|
|
Research & Development |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(1)
|
0
|
(1)
|
(1)
|
(1)
|
|
Depreciation & Amortization |
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(1)
|
(3)
|
(2)
|
(2)
|
(1)
|
(2)
|
(2)
|
(2)
|
(1)
|
(2)
|
(2)
|
(2)
|
(2)
|
|
Other Operating Expenses |
(0)
|
(0)
|
1
|
1
|
(0)
|
1
|
(0)
|
1
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
|
Operating Income |
9
N/A
|
10
+10%
|
12
+23%
|
13
+6%
|
12
-3%
|
15
+20%
|
14
-6%
|
17
+21%
|
18
+8%
|
23
+29%
|
19
-19%
|
29
+53%
|
31
+7%
|
32
+3%
|
23
-28%
|
36
+54%
|
37
+4%
|
35
-5%
|
23
-34%
|
|
Pre-Tax Income | ||||||||||||||||||||
Interest Income Expense |
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
|
Non-Reccuring Items |
(0)
|
0
|
(0)
|
(0)
|
0
|
(0)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
1
|
1
|
1
|
(0)
|
|
Total Other Income |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
1
|
1
|
0
|
|
Pre-Tax Income |
9
N/A
|
10
+10%
|
12
+23%
|
13
+6%
|
12
-3%
|
15
+21%
|
13
-10%
|
17
+27%
|
18
+8%
|
24
+29%
|
19
-20%
|
29
+54%
|
31
+7%
|
32
+5%
|
23
-28%
|
37
+59%
|
39
+4%
|
36
-6%
|
23
-36%
|
|
Net Income | ||||||||||||||||||||
Tax Provision |
(3)
|
(3)
|
(3)
|
(4)
|
(4)
|
(1)
|
1
|
(0)
|
(4)
|
(6)
|
(5)
|
(8)
|
(9)
|
(9)
|
(8)
|
(12)
|
(14)
|
(14)
|
(10)
|
|
Income from Continuing Operations |
6
|
7
|
9
|
9
|
8
|
14
|
14
|
17
|
14
|
18
|
14
|
21
|
22
|
23
|
15
|
25
|
24
|
22
|
13
|
|
Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
|
Net Income (Common) |
6
N/A
|
7
+11%
|
9
+28%
|
9
+5%
|
8
-6%
|
14
+67%
|
14
-1%
|
17
+18%
|
14
-16%
|
18
+28%
|
14
-23%
|
21
+53%
|
22
+6%
|
23
+3%
|
15
-35%
|
25
+67%
|
24
-4%
|
22
-9%
|
13
-42%
|
|
EPS (Diluted) |
0.62
N/A
|
0.68
+10%
|
0.88
+29%
|
0.93
+6%
|
0.87
-6%
|
1.46
+68%
|
1.45
-1%
|
1.71
+18%
|
1.44
-16%
|
1.8
+25%
|
1.42
-21%
|
2.17
+53%
|
2.29
+6%
|
2.38
+4%
|
1.56
-34%
|
2.6
+67%
|
2.5
-4%
|
2.28
-9%
|
1.33
-42%
|